Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Javier G. Casado is active.

Publication


Featured researches published by Javier G. Casado.


Frontiers in Immunology | 2014

Immunomodulatory potential of human adipose mesenchymal stem cells derived exosomes on in vitro stimulated T cells

Rebeca Blázquez; Francisco M. Sánchez-Margallo; Olga de la Rosa; Wilfried Dalemans; Verónica Ãlvarez; Raquel Tarazona; Javier G. Casado

In the recent years, it has been demonstrated that the biological activity of mesenchymal stem cells (MSCs) is mediated through the release of paracrine factors. Many of these factors are released into exosomes, which are small membranous vesicles that participate in cell–cell communication. Exosomes from MSCs are thought to have similar functions to MSCs such as repairing and regeneration of damaged tissue, but little is known about the immunomodulatory effect of these vesicles. Based on an extensive bibliography where the immunomodulatory capacity of MSCs has been demonstrated, here we hypothesized that released exosomes from MSCs may have an immunomodulatory role on the differentiation, activation and function of different lymphocyte subsets. According to this hypothesis, in vitro experiments were performed to characterize the immunomodulatory effect of human adipose MSCs derived exosomes (exo-hASCs) on in vitro stimulated T cells. The phenotypic characterization of cytotoxic and helper T cells (activation and differentiation markers) together with functional assays (proliferation and IFN-γ production) demonstrated that exo-hASCs exerted an inhibitory effect in the differentiation and activation of T cells as well as a reduced T cell proliferation and IFN-γ release on in vitro stimulated cells. In summary, here we demonstrate that MSCs-derived exosomes are a cell-derived product that could be considered as a therapeutic agent for the treatment of inflammation-related diseases.


Immunology and Cell Biology | 2012

Decreased expression of DNAM-1 on NK cells from acute myeloid leukemia patients.

Beatriz Sanchez-Correa; Inmaculada Gayoso; Juan M. Bergua; Javier G. Casado; Sara Morgado; Rafael Solana; Raquel Tarazona

This study tested the hypothesis that the expression of CD112 and CD155 (DNAM‐1 ligands) on leukemic blasts induces a decreased expression of the activating receptor DNAM‐1 on natural killer (NK) cells from acute myeloid leukemia (AML) patients. DNAM‐1 is a co‐receptor involved in the activation of NK cell cytotoxicity after its interaction with its ligands CD112 and CD155 on target cells. Here we study the expression of DNAM‐1 on NK cells and DNAM‐1 ligands on blasts from AML patients stratified by age. The results demonstrate that NK cells from AML patients younger than 65 years have a reduced expression of DNAM‐1 compared with age‐matched controls. The analysis of DNAM‐1 ligands showed a high expression of CD112 and CD155 on leukemic blasts. An inverse correlation between CD112 expression on leukemic blasts and DNAM‐1 expression on NK cells was found. Furthermore, downregulation of DNAM‐1 was induced on healthy donors’ NK cells after in vitro culture with leukemic blasts expressing DNAM‐1 ligands. In conclusion, these results support the hypothesis that receptor–ligand crosslinking downregulates DNAM‐1 expression on NK cells from patients <65 years of age. Considering the relevance of DNAM‐1 in NK recognition and killing of leukemic cells, the reduced expression of this receptor on NK cells from AML patients can represent an additional mechanism of tumor escape.


Stem Cells and Development | 2012

Human Adipose-Derived Stem Cells Impair Natural Killer Cell Function and Exhibit Low Susceptibility to Natural Killer-Mediated Lysis

Olga DelaRosa; Beatriz Sanchez-Correa; Sara Morgado; Cristina Ramírez; Borja del Río; Ramón Menta; Eleuterio Lombardo; Raquel Tarazona; Javier G. Casado

Human adipose-derived stem cells (hASCs) have been successfully used in treating numerous diseases. However, several aspects need to be considered, particularly in the context of allogeneic cell therapy. To better understand hASCs-host interactions, we studied the phenotype of hASCs and their modulatory effect on natural killer (NK) cells by using bone marrow-mesenchymal stem cells (hBM-MSCs) as a reference. The hASCs displayed a lower susceptibility to NK cell-mediated lysis and a lower expression of ligands for DNAM-1 when compared with hBM-MSCs. Moreover, here we demonstrated that hASCs and hBM-MSCs can modulate NK cells through the action of soluble factors such as indoleamine 2,3-dioxygenase. Altogether, these results suggest that for an adoptive cell therapy based on the transfer of allogeneic hASCs, the NK-hASCs crosstalk will not result in an immediate recognition of the transferred cells. Thus, hASCs may remain in the tissue long enough to balance the immune response before being cleared.


AIDS | 2002

NK-associated receptors on CD8 T cells from treatment-naive HIV-infected individuals: defective expression of CD56

Raquel Tarazona; Olga DelaRosa; Javier G. Casado; Julián Torre-Cisneros; Jose L. Villanueva; Maria D. Galiani; José A. Peña; Rafael Solana

Objectives This study addresses the detailed expression of natural killer (NK)- associated receptors on CD8 T lymphocytes in treatment-naive HIV-infected individuals. Design Experimental study analysing the expression of NK-associated receptors on peripheral blood T lymphocytes from HIV-infected individuals compared with healthy controls. Methods Flow cytometry was used to analyse the expression of CD56, CD16, CD94, NKG2A, NKB1, CD161, CD244, and perforin, according to the CD28 phenotype, on CD8bright T cells obtained from treatment-naive HIV-infected individuals and from healthy controls. Results The results showed that CD8bright T cells from treatment-naive HIV-infected individuals had a decreased expression of CD56 and that CD8brightCD56 cell numbers correlated with CD4 cell counts. NK-associated markers were preferentially expressed on CD8brightCD28 negative T cells, both in healthy controls and HIV-infected individuals. An increased expression of CD94, CD244, and perforin, which was the consequence of the expansion of the CD8brightCD28 negative T-cell subset, was also observed in HIV infection. Conclusions As the CD8brightCD56 T cells are the mature cytolytic effector cells, the defective expression of CD56 on CD8bright T cells shown in HIV-infected individuals could be involved in the decreased peripheral blood T-cell cytotoxicity found in HIV infection.


Journal of Innate Immunity | 2011

NK cell recognition and killing of melanoma cells is controlled by multiple activating receptor-ligand interactions.

Sara Morgado; Beatriz Sanchez-Correa; Javier G. Casado; Esther Duran; Inmaculada Gayoso; Fernando Labella; Rafael Solana; Raquel Tarazona

The role of natural killer (NK) cells in tumor immunosurveillance has been recently underlined. A better understanding of the receptor-ligand interactions between NK cells and solid tumor cells is essential for introducing more effective NK cell-based immunotherapy protocols into clinical practice. We previously analyzed the surface expression of ligands for NK cell-activating receptors and costimulatory molecules in a large panel of melanoma cell lines. Although the expression of ligands for NK cell-activating receptors is variable, the majority of melanoma cell lines express ligands for NKG2D and for DNAX accessory molecule-1 (DNAM-1). While the NKG2D receptor has been described as the principal entity responsible for the lysis of several melanoma cell lines, the role of natural cytotoxicity receptors (NCRs) and DNAM-1 receptors in NK cell recognition and killing of melanoma cells has been recently emphasized. Antibody-mediated masking of NKG2D, NCRs, and DNAM-1 has proven that NKG2D, NCRs, and DNAM-1 frequently cooperate in the lysis of melanoma cells. In this work, we provide an overview of recent advances in the study of melanoma cells’ susceptibility to NK cell-mediated lysis and how multiple receptor-ligand interactions participate in melanoma cell elimination.


Molecular Pharmaceutics | 2015

Assessment of the Behavior of Mesenchymal Stem Cells Immobilized in Biomimetic Alginate Microcapsules.

Ane Garate; Jesús Ciriza; Javier G. Casado; Rebeca Blázquez; José Luis Pedraz; Gorka Orive; Rosa María Hernández

The combination of mesenchymal stem cells (MSCs) and biomimetic matrices for cell-based therapies has led to enormous advances, including the field of cell microencapsulation technology. In the present work, we have evaluated the potential of genetically modified MSCs from mice bone marrow, D1-MSCs, immobilized in alginate microcapsules with different RGD (Arg-Gly-Asp) densities. Results demonstrated that the microcapsules represent a suitable platform for D1-MSC encapsulation since cell immobilization into alginate matrices does not affect their main characteristics. The in vitro study showed a higher activity of D1-MSCs when they are immobilized in RGD-modified alginate microcapsules, obtaining the highest therapeutic factor secretion with low and intermediate densities of the bioactive molecule. In addition, the inclusion of RGD increased the differentiation potential of immobilized cells upon specific induction. However, subcutaneous implantation did not induce differentiation of D1-MSCs toward any lineage remaining at an undifferentiated state in vivo.


Journal of Translational Medicine | 2015

Delayed administration of allogeneic cardiac stem cell therapy for acute myocardial infarction could ameliorate adverse remodeling: experimental study in swine.

Verónica Crisóstomo; Claudia Báez-Díaz; Juan Maestre; Monica Garcia-Lindo; Fei Sun; Javier G. Casado; Rebeca Blázquez; Jose Luis Abad; Itziar Palacios; Luis Rodriguez-Borlado; Francisco M. Sánchez-Margallo

BackgroundThe optimal timing of cardiac stem cells administration is still unclear. We assessed the safety of same-day and delayed (one week) delivery and the possible influence of the timing on the therapeutic outcomes of allogeneic porcine cardiac stem cells administration after acute myocardial infarction in a closed-chest ischemia-reperfusion model.MethodsFemale swine surviving 90 min occlusion of the mid left anterior descending coronary artery received an intracoronary injection of 25x106 porcine cardiac stem cells either two hours (n = 5, D0) or 7 days (n = 6, D7) after reperfusion. Controls received intracoronary injection of vehicle on day 7 (n = 6, CON). Safety was defined in terms of absence of major cardiac events, changes to the ECG during injection, post-administration coronary flow assessed using the TIMI scale and cardiac troponin I determination after the intervention. Cardiac Magnetic Resonance was performed for morphological and functional assessment prior to infarction, before injection (D7 and CON groups only), at one and 10 weeks. Samples were taken from the infarct and transition areas for pathological examination.ResultsNo major adverse cardiac events were seen during injection in any group. Animals receiving the therapy on the same day of infarction (D0 group) showed mild transient ST changes during injection (n = 4) and, in one case, slightly compromised coronary flow (TIMI 2). Cardiac function parameters and infarct sizes were not significantly different between groups, with a trend towards higher ejection fraction in the treated groups. Ventricular volumes indexed to body surface area increased over time in control animals, and decreased by the end of the study in animals receiving the therapy, significantly so when comparing End Diastolic Volume between CON and D7 groups (CON: 121.70 ml/m2 ± 26.09 ml/m2, D7: 98.71 ml/m2 ± 8.30 ml/m2, p = 0.037). The treated groups showed less organization of the collagenous scar, and a significantly (p = 0.019) higher amount of larger, more mature vessels at the infarct border.ConclusionsThe intracoronary injection of 25x106 allogeneic cardiac stem cells is generally safe, both early and 7 days after experimental infarction, and alleviates myocardial dysfunction, with a greater limitation of left ventricular remodeling when performed at one week.


PLOS ONE | 2016

Intrapericardial Delivery of Cardiosphere-Derived Cells: An Immunological Study in a Clinically Relevant Large Animal Model.

Rebeca Blázquez; Francisco M. Sánchez-Margallo; Verónica Crisóstomo; Claudia Báez; Juan Maestre; Verónica Álvarez; Javier G. Casado

Introduction The intrapericardial delivery has been defined as an efficient method for pharmacological agent delivery. Here we hypothesize that intrapericardial administration of cardiosphere-derived cells (CDCs) may have an immunomodulatory effect providing an optimal microenvironment for promoting cardiac repair. To our knowledge, this is the first report studying the effects of CDCs for myocardial repair using the intrapericardial delivery route. Material and Methods CDCs lines were isolated, expanded and characterized by flow cytometry and PCR. Their differentiation ability was determined using specific culture media and differential staining. 300,000 CDCs/kg were injected into the pericardial space of a swine myocardial infarcted model. Magnetic resonance imaging, biochemical analysis of pericardial fluid and plasma, cytokine measurements and flow cytometry analysis were performed. Results Our results showed that, phenotype and differentiation behavior of porcine CDCs were equivalent to previously described CDCs. Moreover, the intrapericardial administration of CDCs fulfilled the safety aspects as non-adverse effects were reported. Finally, the phenotypes of resident lymphocytes and TH1 cytokines in the pericardial fluid were significantly altered after CDCs administration. Conclusions The pericardial fluid could be considered as a safe and optimal vehicle for CDCs administration. The observed changes in the studied immunological parameters could exert a modulation in the inflammatory environment of infarcted hearts, indirectly benefiting the endogenous cardiac repair.


PLOS ONE | 2015

Intrapericardial administration of mesenchymal stem cells in a large animal model: a bio-distribution analysis.

Rebeca Blázquez; Francisco M. Sánchez-Margallo; Verónica Crisóstomo; Claudia Báez; Juan Maestre; Monica Garcia-Lindo; Alejandra Usón; Verónica Álvarez; Javier G. Casado

The appropriate administration route for cardiovascular cell therapy is essential to ensure the viability, proliferative potential, homing capacity and implantation of transferred cells. At the present, the intrapericardial administration of pharmacological agents is considered an efficient method for the treatment of cardiovascular diseases. However, only a few reports have addressed the question whether the intrapericardial delivery of Mesenchymal Stem Cells (MSCs) could be an optimal administration route. This work firstly aimed to analyze the pericardial fluid as a cell-delivery vehicle. Moreover, the in vivo biodistribution pattern of intrapericardially administered MSCs was evaluated in a clinically relevant large animal model. Our in vitro results firstly showed that, MSCs viability, proliferative behavior and phenotypic profile were unaffected by exposure to pericardial fluid. Secondly, in vivo cell tracking by magnetic resonance imaging, histological examination and Y-chromosome amplification clearly demonstrated the presence of MSCs in pericardium, ventricles (left and right) and atrium (left and right) when MSCs were administered into the pericardial space. In conclusion, here we demonstrate that pericardial fluid is a suitable vehicle for MSCs and intrapericardial route provides an optimal retention and implantation of MSCs.


Wound Repair and Regeneration | 2014

Mesenchymal stem cell-coated sutures enhance collagen depositions in sutured tissues.

Javier G. Casado; Rebeca Blázquez; Inmaculada Jorge; Verónica Álvarez; Guadalupe Gómez-Mauricio; Mariano Ortega-Muñoz; Jesús Vázquez; Francisco M. Sánchez-Margallo

Sutures are commonly used for surgical procedures and new sutures are being developed to improve wound healing. In the past decade, it has been extensively shown that mesenchymal stem cells (MSCs) have a wound healing potential. To benefit the overall wound healing process, we aimed to analyze the usage of pretreated sutures for improving the implantation of MSCs in the tissues. Our results firstly showed that suture pretreatments with gelatin, poly‐L‐lysine, and NaOH improved the adhesive strength of MSCs to sutures. These cells remained surrounding the sutured tissue and no significant phenotypic changes were found in those cells cultured onto pretreated sutures. In vivo experiments showed that the implantation of MSCs by suturing increases the collagen content in the sutured tissue. Moreover, proteomics analysis of secreted proteins showed that collagen alpha‐1(I) chain was the most abundant collagen found. To our knowledge, this is the first report that aimed to improve the implantation of MSCs in tissue by suture pretreatments. Moreover, in vivo experiments suggest that MSC‐coated sutures may enhance wound healing and tissue remodeling through the release of different collagen types being applicable for those patients that tend to have difficulty healing.

Collaboration


Dive into the Javier G. Casado's collaboration.

Top Co-Authors

Avatar

Raquel Tarazona

University of Extremadura

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Inmaculada Jorge

Centro Nacional de Investigaciones Cardiovasculares

View shared research outputs
Top Co-Authors

Avatar

Sara Morgado

University of Extremadura

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Fei Sun

University of Extremadura

View shared research outputs
Researchain Logo
Decentralizing Knowledge